Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

• Bernard G. Combe,
• Yoshiya Tanaka,
• Maya H. Buch,
• Peter Nash,
• Gerd R. Burmester,
• Alan J. Kivitz,
• Beatrix Bartok,
• Alena Pechonkina,
• Katrina Xia,
• Kahaku Emoto,
• Shungo Kano,
• Thijs K. Hendrikx,
• Robert B. M. Landewé,
• Daniel Aletaha

Affiliations

Bernard G. Combe

Montpellier University

Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health

Maya H. Buch

NIHR Manchester Biomedical Research Centre, University of Manchester

Peter Nash

Griffith University of Queensland

Gerd R. Burmester

Charité University Hospital Berlin

Alan J. Kivitz

Altoona Center for Clinical Research

Beatrix Bartok

Gilead Sciences, Inc.

Alena Pechonkina

Gilead Sciences, Inc.

Katrina Xia

Gilead Sciences, Inc.

Kahaku Emoto

Gilead Sciences K.K.

Shungo Kano

Gilead Sciences K.K.

Thijs K. Hendrikx

Galapagos NV

Robert B. M. Landewé

Amsterdam Rheumatology and Clinical Immunology Center (amC) and Zuyderland MC

Daniel Aletaha

Medical University of Vienna